| Identification | Back Directory | [Name]
2-Cyano-4-methyl-5-[[2-[6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]-2,7-diazaspiro[3.5]non-7-yl]methyl]-1H-indole-1-acetamide | [CAS]
2163769-52-4 | [Synonyms]
BAY-155
2-Cyano-4-methyl-5-[[2-[6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]-2,7-diazaspiro[3.5]non-7-yl]methyl]-1H-indole-1-acetamide
2-[2-Cyano-4-methyl-5-[[2-[6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]-2,7-diazaspiro[3.5]nonan-7-yl]methyl]-1-indolyl]acetamide | [Molecular Formula]
C28H28F3N7OS | [MOL File]
2163769-52-4.mol | [Molecular Weight]
567.63 |
| Hazard Information | Back Directory | [Uses]
BAY-155 is a potent and selective menin-MLL tool inhibitor, with an IC50 of 8 nM. BAY-155 leads to a strong expression down-regulation of the MEIS1 gene and up-regulation of CD11b and MNDA genes. BAY-155 shows anti-proliferative effects in AML/ALL (acute myeloid/lymphoblastic leukemia) models[1]. | [References]
[1] Brzezinka K, et al. Characterization of the Menin-MLL Interaction as Therapeutic Cancer Target. Cancers (Basel). 2020 Jan 14;12(1):201. DOI:10.3390/cancers12010201 |
|
|